Tyra Biosciences (TYRA) said Friday it obtained investigational new drug clearance from the US Food and Drug Administration for TYRA-300, moving to a phase 2 trial of the potential drug for non-muscle invasive bladder cancer.
The phase 2 SURF302 trial targets to enroll up to 90 participants at several sites mainly in the US. Patient dosing is expected to begin in Q2, followed by the initial three-month complete response data, which is the study's primary endpoint, the company said.
TYRA-300 is also set to be evaluated in other phase 2 studies -- BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial carcinoma, the company added.
Shares of the company were down nearly 5% in recent trading.
Price: 15.18, Change: -0.79, Percent Change: -4.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.